Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumor necrosis factor alpha therapy

Bratislava Medical Journal

Volumn 117, Issue 4, 2016, Pages 205-211

  Hlavaty, T ^a   Krajcovicova, A ^a   Letkovsky, J ^a   Sturdik, I ^a   Koller, T ^a   Toth, J ^a   Huorka, M ^a  

^a Bratislava   (Slovakia)

Author keywords

Adalimumab; Crohn's dis ease; Infliximab; Relapse rate; Treatment discontinuation; Ulcerative colitis

Indexed keywords

CALGRANULIN; GASTROINTESTINAL AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TREATMENT WITHDRAWAL;

ADULT; AGED; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 85014813213     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: 10.4149/BLL_2016_039     Document Type: Article

References (24)

1. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353 (23): 2462-2476.
2. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Maintenance infliximab for crohn's disease: The ACCENT I randomised trial. The Lancet 2002; 359 (9317): 1541-1549.
3. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R et al. Adalimumab for maintenance of clinical response and remission in patients with crohn's disease: The CHARM trial. Gastroenterology 2007; 132 (1): 52-65.
4. Hazlewood GS, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH et al. Comparative effectiveness of immunosuppressant and biologics for inducing and maintaining remission in crohn's disease: A network meta-analysis. Gastroenterology 2014; 0 (0).
5. Lv R, Qiao W, Wu Z, Wang Y, Dai S, Liu Q, Zheng X. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: A meta-analysis. PLoS On e 2014; 9(1): e86692.
6. Colombel JF, Loftus EVJ, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD et al. The safety profile of infliximab in patients with crohn's disease: The mayo clinic experience in 500 patients. Gastroenterology 2004; 126 (1): 19-31.
7. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM et al. Serious infections and mortality in association with therapies for crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4 (5): 621-630.
8. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6 (6): 644-653.
9. Burisch J, Vardi H, Pedersen N, Brinar M, Cukovic-Cavka S, Kaimakliotis I et al. Costs and resource utilization for diagnosis and treatment during the initial year in a european inflammatory bowel disease inception cohort: An ecco-epicom study. Inflamm Bowel Dis 2015; 21 (1): 121-131.
10. Pittet V, Froehlich F, Maillard MH, Mottet C, Gonvers JJ, Felley C et al. When do we dare to stop biological or immunomodulatory therapy for crohn's disease? Results of a multidisciplinary european expert panel. J Crohns Colitis 2013; 7 (10): 820-826.
11. Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA. Clinical evolution of luminal and perianal crohn's disease after inducing remission with infliximab: How long should patients be treated? Aliment Pharmacol Ther 2005; 22 (11-12): 1107-1113.
12. Waugh AW, Garg S, Matic K, Gramlich L, Wong C, Sadowski DC et al. Maintenance of clinical benefit in crohn's disease patients after discontinuation of infliximab: Long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010; 32 (9): 1129-1134.
13. Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D et al. Maintenance of remission among patients with crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142 (1): 63-70.
14. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 montreal world congress of gastroenterology. Can J Gastroenterol 2005; 19 Suppl A: 5A-36A.
15. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92 (6): 1894-1898.
16. Harvey RF, Bradshaw JM. A simple index of crohn's-disease activity. Lancet 1980; 1(8167): 514, Pubmed ID: http://www.ncbi.nlm.nih. gov/pubmed/6102236
17. Irvine EJ, Zhou Q, Thompson AK. The short inflammatory bowel disease questionnaire: A quality of life instrument for community physicians managing inflammatory bowel disease. American Journal of Gastroenterology 1996; 91 (8).
18. Hlavaty T, Persoons P, Vermeire S, Ferrante M, Pierik M, Van Assche G, Rutgeerts P. Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in crohn's disease. Inflamm Bowel Dis 2006; 12 (3): 199-204.
19. Lu C, Waugh A, Bailey RJ, Cherry R, Dieleman LA, Gramlich L et al. Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation. World J Gastroenterol 2012; 18 (36): 5058-5064.
20. Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Østergaard Thomsen O, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: An observational danish single center study. Scand J Gastroenterol 2012; 47 (5): 518-527.
21. Molnár T, Lakatos PL, Farkas K, Nagy F, Szepes Z, Miheller P et al. Predictors of relapse in patients with crohn's disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther 2013; 37 (2): 225-233.
22. Farkas K, Lakatos PL, Nagy F, Szepes Z, Miheller P, Papp M et al. Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. Scand J Gastroenterol 2013; 48 (12): 1394-1398.
23. Papamichael K, Casteele NV, Gils A, Tops S, Hauenstein S, Singh S et al. Long-Term outcome of patients with crohn's disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol 2014.
24. Molander P, Färkkilä M, Salminen K, Kemppainen H, Blomster T, Koskela R et al. Outcome after discontinuation of tnfa-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis 2014; 20 (6): 1021-1028.